Clinical trials: Elevated LDL Cholesterol, active
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Disease
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C.
- Trial name
- AZURE-LDL (NCT07000123)
- Testing
- AZD0780
- Where
- 404 sites in United States, Argentina and 20 more
- Volunteers
- 3,103 people
- Sponsor
- AstraZeneca
Atherosclerosis, Cardiovascular Disease
A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
- Conditions
- Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
- Trial name
- HEART-3 (NCT07839936)
- Testing
- VERVE-102
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Verve Therapeutics, Inc.
Hypercholesterolemia
Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
A multicenter study to evaluate safety and efficacy of inclisiran in Asian patients with ASCVD or ASCVD high risk and elevated LDL-C
- Trial name
- NCT04765657
- Testing
- inclisiran sodium
- Where
- 45 sites in China, Singapore and 2 more
- Volunteers
- 345 people
- Sponsor
- Novartis Pharmaceuticals
Primary Hypercholesterolemia or Mixed Hyperlipidemia
QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
To evaluate the efficacy, safety and immunogenicity of QCL7401 subcutaneous administration in patients with primary hypercholesterolemia or mixed hyperlipidemia with poorly controlled LDL-C elevated on optimized lipid-lowering…
- Trial name
- NCT07441317
- Testing
- QLC7401
- Volunteers
- 780 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Elevated LDL-C and High Cholesterol
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. STX-1150 does not edit or permanently change the gene.
- Trial name
- STX-1150-01 (NCT07428473)
- Testing
- STX-1150
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 64 people
- Sponsor
- Monash University
ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction
Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)
Intensive Lipid-Lowering Therapy guided by a cloud-based Software System (CLIMEDO GmbH) improves (European Society of Cardiolofgy/European Atherosclerosis Society) ESC/EAS-guideline recommended LDL-cholesterol target attainment…
- Conditions
- ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction, LDL-cholesterol
- Trial name
- GoT (NCT05587621)
- Testing
- statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran
- Where
- 10 sites in Germany
- Volunteers
- 300 people
- Sponsor
- Jena University Hospital
Hypercholesterolaemia, Familial Hypercholesterolaemia
An Observational Study to Evaluate Treatment Patterns in High, Very High and Extreme Cardiovascular Risk Patients With Hypercholesterolemia, Including Familial Hypercholesterolemia
TRAP-HC is a multicenter, observational, longitudinal, prospective study designed to evaluate real-world treatment patterns and lipid-lowering therapy (LLT) management in patients with hypercholesterolemia, including familial…
- Conditions
- Hypercholesterolaemia, Familial Hypercholesterolaemia, CVD Risk
- Trial name
- TRAP-HC (NCT07606118)
- Volunteers
- 2,500 people
- Sponsor
- Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
Hypercholesterolaemia
LATAM LOWERS LDL-C
This is an open label, patient-level 1:1 randomized clinical trial in a multi-country study aiming to evaluate the real-world impact of inclisiran + Usual Care (UC) vs UC alone on LDL-C lowering, patient-reported outcomes, and…
- Trial name
- NCT06501443
- Testing
- Usual care, KJX839
- Where
- 11 sites in Argentina, Brazil
- Volunteers
- 520 people
- Sponsor
- Novartis Pharmaceuticals
High Cholesterol
Effect of Herring Oil Concentrate on LDL Cholesterol Concentration in Adults
High cholesterol concentration is a major risk factor for cardiovascular disease (CVD), and consumption of fish has been associated with a lower CVD risk in several studies.
- Trial name
- NCT06364163
- Testing
- Herring oil concentrate, Control
- Where
- Norway
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Bergen
Myocardial Infarction (MI), Dyslipidemias
Germany on Target Registry
Germany on Target Registry (DaZiR) is a prospective, Germany-wide patient registry designed to assess lipid management and low-density lipoprotein cholesterol ( LDL-C) target attainment in adults following acute myocardial…
- Trial name
- DaZiR (NCT07835282)
- Testing
- No study-assigned intervention
- Volunteers
- 10,000 people
- Sponsor
- Deutsche Gesellschaft für Lipidologie e. V. (DGFL) - Lipid-Liga
Healthy Participants, Dyslipidemia
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4954 in healthy participants with or without elevated Lipoprotein(a)…
- Trial name
- NCT06980428
- Testing
- AZD4954
- Where
- 6 sites in United States
- Volunteers
- 171 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides
A multicenter, randomized, double-blind, phase Ⅳ study to evaluate the long-term efficacy and safety of Pitavastatin/Ezetimibe and Pitavastatin in patients with hypercholesterolemia with elevated triglycerides
- Trial name
- NCT07442630
- Testing
- Pitavastatin 4mg, Ezetimibe 10 mg
- Where
- South Korea
- Volunteers
- 88 people
- Sponsor
- JW Pharmaceutical
Inclisiran Formulation
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
The purpose of this study is to compare safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the currently marketed formulation of inclisiran with a new formulation containing polysorbate 80 (PS80), after a…
- Trial name
- NCT07626281
- Testing
- Inclisiran formulation containing PS80, Currently marketed inclisiran formulation
- Where
- 6 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
ASCVD, LDL-C
Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?
The goal of this implementation trial is to learn if providing education to doctors and patients who have had a heart event works to prevent future heart problems. The main questions it aims to answer are: 1.
- Trial name
- T2T (NCT06471036)
- Testing
- Care Champion Intervention
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Duke University
Borderline High LDL-cholesterol
Effects of Ubiquinol and Ubiquinone on Vascular Function in Healthy Adults With Borderline High LDL-Cholesterol
This randomized, double-blind, placebo-controlled clinical trial will evaluate the effects of Ubiquinol and Ubiquinone on vascular endothelial function in generally healthy adults with borderline high LDL-cholesterol.
- Trial name
- NCT07881601
- Testing
- Ubiquinol, Ubiquinone
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- SF Research Institute, Inc.
Plaque, Atherosclerotic
Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction
This study is to evaluate the effect of Inclisiran on coronary atherosclerosis using intravascular ultrasound (IVUS) and optical coherence tomography (OCT) in patients with acute myocardial infarction and elevated low-density…
- Trial name
- V-ACCELERATE (NCT06372925)
- Testing
- atorvastatin, IVUS/OCT, inclisiran
- Where
- 19 sites in China
- Volunteers
- 318 people
- Sponsor
- Novartis Pharmaceuticals
Elevated LDL Cholesterol
Cardioprotective and Mental Health Benefits of the MIND Diet Combined With Forest Bathing
This randomized controlled trial aims to study the effects of the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet combined with forest bathing (FB) on reducing cardiovascular disease (CVD) risk factors in…
- Trial name
- NCT06222632
- Testing
- Mind diet intervention, Mind plus FB intervention, Usual care
- Where
- Hong Kong
- Volunteers
- 273 people
- Sponsor
- Tung Wah College
Primary Hypercholesterolemia or Mixed Hyperlipidemia
Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol
To evaluate the efficacy, safety, pharmacodynamics and immunogenicity of QLC7401 subcutaneous administration in patients with primary hypercholesterolemia or mixed hyperlipidemia with poorly controlled LDL-C elevated on optimized…
- Trial name
- NCT06750341
- Testing
- QLC7401
- Volunteers
- 156 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Peripheral Artery Disease, Polyvascular Disease
Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)
Patients with atherosclerotic peripheral artery disease often have combined coronary artery disease or cerebral artery disease and show high rates of cardiovascular mortality and morbidities.
- Trial name
- NCT06231966
- Testing
- Combination therapy of high-intensity dose rosuvastatin and ezetimibe, Rosuvastatin monotherapy for treat-to-target
- Where
- South Korea
- Volunteers
- 2,462 people
- Sponsor
- Yonsei University